戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 erating cysticercus and will also respond to symptomatic treatment.
2 lemental oxygenation, and they received only symptomatic treatment.
3 rely on the off-label use of medications for symptomatic treatment.
4 icant differences in their responsiveness to symptomatic treatment.
5 enal diseases that are frequently limited to symptomatic treatment.
6 lecular imbalance may be more effective than symptomatic treatment.
7 se of the condition favourably compared with symptomatic treatment.
8      Corticosteroids could be an alternative symptomatic treatment.
9 t person at the right time, rather than just symptomatic treatment.
10 ly to be underdiagnosed and can benefit from symptomatic treatment.
11 nd quality of life and time to initiation of symptomatic treatment.
12 Currently, there is no cure for asthma, only symptomatic treatment.
13 e-phenotype correlations, and the effects of symptomatic treatment.
14 ound studies in both neurorehabilitation and symptomatic treatment.
15 t the value of therapeutic interventions for symptomatic treatment.
16  and currently there is no cure for PD, only symptomatic treatments.
17 erapy for ADO2, and patients usually receive symptomatic treatments.
18 es, which are currently managed primarily by symptomatic treatments.
19 ociated with high morbidity and lacks proven symptomatic treatments.
20 ation of their cardiomyopathy in addition to symptomatic treatments.
21 eater share of disease-modifying rather than symptomatic treatments.
22 ic patients who were unresponsive to optimal symptomatic treatments.
23 other maintenance immunotherapies as well as symptomatic treatments.
24 vational data gathered on symptomatology and symptomatic treatments.
25 TSC-related research and challenged existing symptomatic treatments.
26 eath will be developed to complement current symptomatic treatments.
27 bo (n = 81); 92% concurrently used 1 or more symptomatic treatments (94% for amoxicillin group vs 90%
28                             Our data suggest symptomatic treatment alone for immunocompetent patients
29 ; 55% women) with early PD not yet requiring symptomatic treatment and a serum urate concentration le
30 ent patterns through a process of education, symptomatic treatment and cognitive behavioural therapy
31 neurodegeneration are needed to enable early symptomatic treatment and enable identification of peopl
32                                              Symptomatic treatment and reassurance is the preferred i
33 is, the relatively few evaluative studies in symptomatic treatment and rehabilitation have meant that
34                                              Symptomatic treatment and the currently available therap
35 her therapeutic agents, appear warranted, as symptomatic treatments and neuroprotective treatments ar
36 atients regarding smoking cessation, provide symptomatic treatment, and eventually develop disease-mo
37 (nine patients) response to immunotherapy or symptomatic treatment, and three died.
38 ntimalarial drug use, antibiotic use, use of symptomatic treatments, and mortality rates.
39                                   Many other symptomatic treatments appear helpful to individuals in
40 immunodeficiency virus (HIV) but few data on symptomatic treatment are available.
41 matic treatments for RBD, clinical trials of symptomatic treatments are also needed to identify evide
42                                To date, only symptomatic treatments are available involving acetylcho
43 e, neurodegenerative disorder for which only symptomatic treatments are available.
44                            Although the main symptomatic treatments are intranasal corticosteroids (I
45                              The options for symptomatic treatments are limited, but a potential targ
46                                              Symptomatic treatments are modestly effective and offer
47                                              Symptomatic treatments are quite effective in early dise
48                     This and other trials of symptomatic treatments are reviewed.
49 Cox proportional hazards model using time to symptomatic treatment as the dependent variable.
50 clude oral therapies, monoclonal antibodies, symptomatic treatments as well as insights into neuropro
51  devices manipulating neuronal signaling for symptomatic treatment, becoming more precise and disease
52        Medical care has long been limited to symptomatic treatments, but first-in-class PMD therapies
53     Future studies should be directed at pre-symptomatic treatment by exploring ways to maintain nucl
54                                     Although symptomatic treatment by the dopamine precursor levodopa
55                                    Effective symptomatic treatment can be achieved with medication an
56 erstanding of aetiology, pathophysiology and symptomatic treatments can arise from a transdiagnostic
57                                          For symptomatic treatment clinical trials, objective polysom
58 trategies that would expand upon the limited symptomatic treatments currently available for this prog
59                      In rare cases for which symptomatic treatment does not control dyspnoea to the p
60 ificantly alter the disease course, but many symptomatic treatments exist to improve patients' qualit
61                   Although there is no cure, symptomatic treatments exist.
62      Surgery should be reserved for severely symptomatic treatment failures.
63 thylsiloxane polyhdrate) is recommended as a symptomatic treatment for acute diarrhoea and chronic di
64                        The current frontline symptomatic treatment for Alzheimer's disease (AD) is wh
65 ed to a non-AIT control group receiving only symptomatic treatment for AR for up to 6 years.
66 rgeting IL-1beta signaling may offer a novel symptomatic treatment for CJD.SIGNIFICANCE STATEMENT Dem
67     Resynchronization pacing is an effective symptomatic treatment for heart failure patients with pr
68 ep brain stimulation therapy is an effective symptomatic treatment for Parkinson's disease, yet the p
69 ate diagnosis is important because effective symptomatic treatment for PD is available.
70                              Currently, only symptomatic treatment for PD is available.
71  and emphasize the importance of appropriate symptomatic treatment for these individuals.
72     To address the ongoing need for improved symptomatic treatments for individuals with Huntington's
73 ll patients received a 5- to 7-day supply of symptomatic treatments for pain, fever, cough, and nasal
74 dopa and the dopamine agonists are effective symptomatic treatments for Parkinson's disease, and all
75 epam and melatonin are most commonly used as symptomatic treatments for RBD, clinical trials of sympt
76 dentified genes, and innovative experimental symptomatic treatments for these devastating disorders.
77 ate model of PD that could be useful to test symptomatic treatments for these heavily disabling sympt
78 eting pharmacological or non-pharmacological symptomatic treatment in ALS are examples of areas that
79 t application of antimicrobial strategies as symptomatic treatment in coronavirus disease (COVID-19)
80 ence supports the use of levodopa as initial symptomatic treatment in most patients with Parkinson's
81               There is no reason to postpone symptomatic treatment in people developing disability du
82 E inhibitors, which are potentially superior symptomatic treatments in late-stage Alzheimer's disease
83                                              Symptomatic treatment includes cholestyramine and antidi
84                                              Symptomatic treatment includes supplementing fiber to ac
85                       There is no cure, only symptomatic treatment is available.
86                               Palliative and symptomatic treatment is based on surgical debulking, tu
87                              The mainstay of symptomatic treatment is levodopa.
88 median 3-year follow-up of 132 patients with symptomatic treatment-naive and relapsed/refractory CLL
89 itiated trial of ibrutinib and venetoclax in symptomatic treatment-naive patients with MYD88-mutated
90 ce for multisystem involvement and effective symptomatic treatment, new endeavours are underway to fi
91 mmunotherapy tablet in addition to effective symptomatic treatment of allergic rhinoconjunctivitis.
92 tylcholinesterase inhibitors (AChEIs) during symptomatic treatment of Alzheimer's disease, we report
93 (AChE) inhibitor, currently approved for the symptomatic treatment of Alzheimer's disease, with possi
94 acetylcholinesterase inhibitors approved for symptomatic treatment of Alzheimer's disease.
95        Methylphenidate (MPH) is an effective symptomatic treatment of attention deficit hyperactivity
96 cal disorders and indicate the potential for symptomatic treatment of behavioural variant frontotempo
97 duration was not superior to placebo for the symptomatic treatment of certain types of ataxia.
98 the approval of this class of agents for the symptomatic treatment of CHF, but long-term studies are
99            EGb 761 is used worldwide for the symptomatic treatment of cognitive disorders due to its
100  active Amaryllidaceae alkaloid used for the symptomatic treatment of early onset Alzheimer's disease
101          The average optimal contact used in symptomatic treatment of early PD patients was: anterior
102 el and functionally selective target for the symptomatic treatment of excessive weight gain associate
103 t 3,4-diaminopyridine may play a role in the symptomatic treatment of fatigue in multiple sclerosis.
104  anticholinergic agent, may be useful in the symptomatic treatment of functional bowel disorders.
105 Recommendations for conservative management, symptomatic treatment of headache and management of comp
106 Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether
107     Diuretics are a mainstay therapy for the symptomatic treatment of heart failure.
108 nhibitor tetrabenazine, presently in use for symptomatic treatment of hyperkinetic disorders.
109  Compounds of this type may be useful in the symptomatic treatment of memory impairment associated wi
110 herapeutic potential of cannabinoids for the symptomatic treatment of MS are ongoing, and this study
111 s, have emerged as validated targets for the symptomatic treatment of neurological diseases such as s
112                                              Symptomatic treatment of neuropathic pain in small fibre
113 e, an oral prokinetic drug indicated for the symptomatic treatment of nocturnal heartburn due to gast
114 cyclooxygenase-2 inhibitor developed for the symptomatic treatment of osteoarthritis and acute pain.
115 lation (DBS) of the subthalamic nucleus is a symptomatic treatment of Parkinson's disease but benefit
116 effective pharmacological agent used for the symptomatic treatment of Parkinson's disease but long-te
117       Although progress has been made in the symptomatic treatment of Parkinson's disease since the d
118        L-DOPA has been the gold standard for symptomatic treatment of Parkinson's disease.
119 nting, steady advances are being made in the symptomatic treatment of Parkinson's disease.
120 ceptor subtypes as potential targets for the symptomatic treatment of parkinsonian-like motor symptom
121 ventral pallidotomy has been employed in the symptomatic treatment of patients with advanced Parkinso
122 n proposed recently as an alternative in the symptomatic treatment of patients with hypertrophic obst
123 reotide has some efficacy and is safe in the symptomatic treatment of patients with inoperable bowel
124 s (K(V)1 family) clinically approved for the symptomatic treatment of patients with multiple sclerosi
125 cated as a useful adjunct to levodopa in the symptomatic treatment of patients with PD with and witho
126 rainage in ERCP is an established method for symptomatic treatment of patients with unresectable mali
127 een suggested as an alternative approach for symptomatic treatment of PD.
128                                              Symptomatic treatment of SOD1(G93A) mice from 70 days of
129 dies demonstrate cannabinoids are useful for symptomatic treatment of spasticity and tremor in chroni
130 ically available drugs may be beneficial for symptomatic treatment of the disease.
131 the data have potential implications for the symptomatic treatment of the disease.
132 vention is likely to remain important in the symptomatic treatment of this disabling disease.
133                         Oral salbutamol is a symptomatic treatment option in survivors.
134 for LEMS, and the current most commonly used symptomatic treatment option is a potassium channel bloc
135                              Currently, only symptomatic treatment options are available.
136                                         Post-symptomatic treatment relieved toxic signs of botulism a
137                                     Although symptomatic treatments remain scarce, emerging evidence
138 and anticholinergic medications are used for symptomatic treatment, significant deficits in cholinerg
139 nt is still elusive, the currently available symptomatic treatment strategies are quite effective for
140 dementia, which helps to guide clinicians in symptomatic treatment strategies.
141 ement of neurological complications includes symptomatic treatments such as antiepileptic drugs or ce
142 ate key aspects of disease pathology and its symptomatic treatment suggests that this neuromuscular j
143            Parkinson disease (PD) has useful symptomatic treatments that do not slow the neurodegener
144 review article focuses on the most efficient symptomatic treatments-that is using more and more speci
145              In contrast to first-generation symptomatic treatments, the new disease-modifying precis
146 inopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disabilit
147 of therapeutic strategies--from conservative symptomatic treatment to curative hematopoietic stem cel
148 areness that health care must move from post-symptomatic treatment to presymptomatic intervention.
149  (CF), shifts the paradigm from conventional symptomatic treatments to therapeutics directly tackling
150 tomatic Prevention trial patients, and 2,567 symptomatic Treatment trial patients.
151 d they support a transdiagnostic approach to symptomatic treatment trials in patients with clinical s
152 ive framework for both disease-modifying and symptomatic treatment trials in RBD is described, includ
153  should be based on MG subgroup and includes symptomatic treatment using acetylcholinesterase inhibit
154 e same time, we evaluated the indications of symptomatic treatment using ASCA score.
155                                              Symptomatic treatment using cholinergic drugs may thus b
156 y, we note that only early and generally pre-symptomatic treatment was effective, and kidney impairme
157                                              Symptomatic treatment was mostly ineffective or produced
158    Taken together, our findings suggest that symptomatic treatment with BI 409306 can restore social
159                Management strategies include symptomatic treatment with corticosteroids and anticonvu
160 uced diarrhea (CID) has customarily involved symptomatic treatment with opioids in conjunction with s
161                                              Symptomatic treatment with stimulant and anticataplectic

 
Page Top